Larimar Therapeutics, Inc. Common Stock
LRMRLarimar Therapeutics, Inc. is a biotechnology company focused on developing treatments for rare and genetically defined diseases. The company utilizes its proprietary drug delivery platform to develop therapies targeting disorders such as Friedreich's ataxia and other neurodegenerative and metabolic conditions. Founded with an emphasis on innovative approaches to challenging diseases, Larimar aims to improve patient outcomes through novel therapeutic solutions.
Company News
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
DJS Law Group is investigating Larimar Therapeutics for potential securities law violations after a clinical study revealed severe allergic reactions, causing the company's stock to drop 33.66%.
The Schall Law Firm is investigating potential securities law violations by Larimar Therapeutics after the company reported study data with severe allergic reactions, causing a significant stock price drop.
Larimar Therapeutics reported allergic reactions in a pivotal study for nomlabofusp, a treatment for Friedreich's ataxia. Seven participants experienced anaphylaxis, leading to study modifications and stock price decline.
Larimar Therapeutics reported positive results from its ongoing study of nomlabofusp, a potential treatment for Friedreich's Ataxia, showing increased frataxin levels and potential clinical improvements, despite experiencing some anaphylaxis events.
